Phosphodiesterase-4 inhibitors: a review of current developments (2010–2012)
A Gavaldà, RS Roberts - Expert opinion on therapeutic patents, 2013 - Taylor & Francis
Introduction: At last, after many years of research, roflumilast has become the first oral
phosphodiesterase-4 inhibitor to be approved by the medical agencies as an add-on …
phosphodiesterase-4 inhibitor to be approved by the medical agencies as an add-on …
Phosphodiesterase-4 inhibitors: a review of current developments (2010-2012)
A Gavaldà, RS Roberts - Expert opinion on therapeutic …, 2013 - pubmed.ncbi.nlm.nih.gov
Introduction At last, after many years of research, roflumilast has become the first oral
phosphodiesterase-4 inhibitor to be approved by the medical agencies as an add-on …
phosphodiesterase-4 inhibitor to be approved by the medical agencies as an add-on …
[引用][C] Phosphodiesterase-4 inhibitors: a review of current developments (2010–2012)
A Gavaldà, RS Roberts - Expert Opinion on Therapeutic Patents, 2013 - cir.nii.ac.jp
Phosphodiesterase-4 inhibitors: a review of current developments (2010 – 2012) | CiNii
Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 …
Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 …
Phosphodiesterase-4 inhibitors: a review of current developments (2010-2012).
A Gavaldà, RS Roberts - Expert Opinion on Therapeutic Patents, 2013 - europepmc.org
At last, after many years of research, roflumilast has become the first oral phosphodiesterase-
4 inhibitor to be approved by the medical agencies as an add-on therapy for chronic …
4 inhibitor to be approved by the medical agencies as an add-on therapy for chronic …